Author: Yoo, Esther M.; Chintalacharuvu, Koteswara R.; Morrison, Sherie L.
Title: Recombinant IgA Antibodies Cord-id: xtqh0p8z Document date: 2007_1_1
ID: xtqh0p8z
Snippet: The production of monoclonal antibodies and the development of recombinant antibody technology have made antibodies one of the largest classes of drugs in development for prophylactic, therapeutic and diagnostic purposes. Currently, all of the Food and Drug Administration (FDA)- approved antibodies are immunoglobulin Gs (IgGs). However, more than 95%of the infections are initiated at the mucosal surfaces, where IgA is the primary immune effector antibody.
Document: The production of monoclonal antibodies and the development of recombinant antibody technology have made antibodies one of the largest classes of drugs in development for prophylactic, therapeutic and diagnostic purposes. Currently, all of the Food and Drug Administration (FDA)- approved antibodies are immunoglobulin Gs (IgGs). However, more than 95%of the infections are initiated at the mucosal surfaces, where IgA is the primary immune effector antibody.
Search related documents:
Co phrase search for related documents- absence presence and low efficiency: 1, 2
- absence presence and lung eosinophilia: 1
- absence presence and lymphoid cell: 1, 2
- addition site and local administration: 1
Co phrase search for related documents, hyperlinks ordered by date